Updates from MaaT Pharma’s Early Access Program Demonstrate Prolonged Long-Term Survival in Patients Receiving MaaT013
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced updated […]